Abstract Number: 2676 • ACR Convergence 2025
Tofacitinib in Juvenile spondyloarthropathy: clinical efficacy, impact on biomarkers and comparison with Adalimumab
Background/Purpose: Tofacitinib is a JAK inhibitor that has been approved for treatment of polyarticular Juvenile idiopathic arthritis. However, data on its use in juvenile spondyloarthropathy…Abstract Number: 2130 • ACR Convergence 2025
Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a chronic disease that results in significant morbidity and mortality in children1. Improved understanding of the pathophysiology of…Abstract Number: 1274 • ACR Convergence 2025
Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation
Background/Purpose: Juvenile idiopathic arthritis is the most common group of inflammatory rheumatic diseases in childhood. Its early onset and the immunosuppressive treatments used to control…Abstract Number: 0424 • ACR Convergence 2025
Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic arthritis in children, but its diagnosis is often challenging due to overlapping symptoms with other…Abstract Number: 0415 • ACR Convergence 2025
The Impact of Social Vulnerability Index Scores in Pediatric Uveitis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children with uveitis as the most common extra-articular manifestation. Uveitis can lead to…Abstract Number: 0397 • ACR Convergence 2025
Paediatric uveitis – Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom
Background/Purpose: Cataract is one of the most common and visually debilitating complications of paediatric uveitis developing as a consequence of chronic inflammation and steroid use.…Abstract Number: 0393 • ACR Convergence 2024
Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…Abstract Number: 1309 • ACR Convergence 2024
Bridging the Gap: Evaluating Ophthalmology Training Amongst Pediatric Rheumatology Fellows
Background/Purpose: The scarcity of literature surrounding ophthalmology training within non-ophthalmology specialties is striking. Chan et al. highlighted this gap revealing a discomfort among family medicine…Abstract Number: 1771 • ACR Convergence 2024
Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of…Abstract Number: 1915 • ACR Convergence 2024
Patient-reported Difficulties Regarding Reproductive Health Discussions in an Urban Outpatient Setting
Background/Purpose: Timely reproductive health conversations in the rheumatology outpatient setting are essential for optimal maternal-fetal health; however, the literature suggests that these conversations happen for…Abstract Number: 1945 • ACR Convergence 2024
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program: 2024 Updates
Background/Purpose: The transition period from pediatric to adult-oriented rheumatology care is a high-risk time for disease flare and poor outcomes. We previously demonstrated implementation of…Abstract Number: 0359 • ACR Convergence 2023
Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment
Background/Purpose: Adalimumab therapeutic drug monitoring (TDM) using established trough concentrations is not standard practice in JIA patients, unlike IBD. No specific guidelines outline a therapeutic…Abstract Number: 0364 • ACR Convergence 2023
Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis
Background/Purpose: The extent to which heterogeneity exists in youth with axial disease and juvenile spondyloarthritis (JSpA) is unclear. In a cross-sectional sample of patients classified…Abstract Number: 0831 • ACR Convergence 2023
Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study
Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…Abstract Number: 018 • 2023 Pediatric Rheumatology Symposium
Using the Electronic Health Record to Identify Subjects with Rheumatic Disease
Background/Purpose: Research teams spend hours manually searching the electronic health records (EHRs) to identify potential candidates eligible for recruitment to the Childhood Arthritis and Rheumatology…